血液透析和腹膜透析患者在接种第三剂mRNA BNT162b2疫苗6个月后体液免疫反应减弱但持续存在。 - Suppr

Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients.

作者信息

Housset Pierre, Kubab Sabah, Pardon Agathe, Vittoz Nathalie, Bozman Dogan-Firat, Hanafi Latifa, Caudwell Valérie, Faucon Anne-Laure

机构信息

Department of Nephrology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France.

Department of Microbiology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France.

出版信息

J Nephrol. 2022 Apr;35(3):783-785. doi: 10.1007/s40620-022-01276-2. Epub 2022 Feb 22.

DOI:10.1007/s40620-022-01276-2

PMID:35192157

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8861617/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec96/8861617/f1169ea75755/40620_2022_1276_Fig1_HTML.jpg

相似文献

Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients.血液透析和腹膜透析患者在接种第三剂mRNA BNT162b2疫苗6个月后体液免疫反应减弱但持续存在。

J Nephrol. 2022 Apr;35(3):783-785. doi: 10.1007/s40620-022-01276-2. Epub 2022 Feb 22.

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.维持性血液透析或腹膜透析患者接种第三剂 BNT162b2 疫苗后的 SARS-CoV-2 抗体反应。

Am J Kidney Dis. 2022 Feb;79(2):185-192.e1. doi: 10.1053/j.ajkd.2021.08.005. Epub 2021 Sep 8.

Perit Dial Int. 2022 Jan;42(1):100-101. doi: 10.1177/08968608211055631. Epub 2021 Nov 9.

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.血液透析患者接种3剂BNT162b2 mRNA新冠疫苗后的体液免疫反应。

Kidney Int. 2021 Sep;100(3):702-704. doi: 10.1016/j.kint.2021.06.025. Epub 2021 Jun 30.

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.血液透析患者接种mRNA-BNT162b2疫苗6个月后体液免疫反应减弱：是时候加强接种了。

Kidney Int. 2021 Dec;100(6):1334-1335. doi: 10.1016/j.kint.2021.10.006. Epub 2021 Oct 14.

Humoral response to BNT162b2 mRNA COVID-19 vaccine in peritoneal and hemodialysis patients: A comparative study.腹膜透析和血液透析患者对 BNT162b2 mRNA COVID-19 疫苗的体液反应：一项比较研究。

Ther Apher Dial. 2022 Aug;26(4):790-796. doi: 10.1111/1744-9987.13766. Epub 2021 Dec 14.

Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up.BNT162b2 mRNA 疫苗对肾移植和慢性透析患者的影响：3-5 个月随访结果。

J Nephrol. 2022 Jan;35(1):153-164. doi: 10.1007/s40620-021-01210-y. Epub 2022 Jan 6.

Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA 新冠病毒疫苗接种后长期血液透析患者中产生强烈细胞和体液免疫应答。

Front Immunol. 2022 Mar 23;13:845882. doi: 10.3389/fimmu.2022.845882. eCollection 2022.

Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis.血液透析患者对两种不同的 mRNA COVID-19 疫苗的抗体反应比较。

J Nephrol. 2022 Jan;35(1):143-151. doi: 10.1007/s40620-021-01195-8. Epub 2022 Jan 3.

A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.一项前瞻性观察研究，旨在验证在接受维持性血液透析的患者中接种第三剂 mRNA 疫苗的合理性、安全性和有效性。

Kidney Int. 2022 Feb;101(2):390-402. doi: 10.1016/j.kint.2021.10.040. Epub 2021 Nov 29.

引用本文的文献

Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave.奥密克戎毒株流行期间腹膜透析患者接种mRNA-1273加强针后的持久抗SARS-CoV-2抗体反应

Vaccines (Basel). 2023 Jun 19;11(6):1121. doi: 10.3390/vaccines11061121.

Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.免疫抑制治疗和新型冠状病毒2型疫苗类型对慢性肾脏病或肾脏替代治疗患者三次接种疫苗后抗体水平的影响

Clin Kidney J. 2022 Nov 24;16(3):528-540. doi: 10.1093/ckj/sfac249. eCollection 2023 Mar.

Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir.接受莫努匹韦治疗的 COVID-19 血液透析患者中，SARS-CoV-2 疫苗加强针的真实世界有效性。

Viruses. 2023 Feb 16;15(2):543. doi: 10.3390/v15020543.

Immunogenicity Rates after SARS-CoV-2 Three-Dose Vaccination in Patients under Dialysis: A Systematic Review and Meta-Analysis.透析患者接种三剂严重急性呼吸综合征冠状病毒2疫苗后的免疫原性率：一项系统评价和荟萃分析。

Vaccines (Basel). 2022 Dec 2;10(12):2070. doi: 10.3390/vaccines10122070.

[Not Available].[不可用]。

Nefrologia. 2022 Dec 16. doi: 10.1016/j.nefro.2022.12.006.

Waning immunity to SARS-CoV-2 following vaccination or infection.接种疫苗或感染新冠病毒后对新冠病毒免疫力的减弱。

Front Med (Lausanne). 2022 Oct 13;9:972083. doi: 10.3389/fmed.2022.972083. eCollection 2022.

Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis.腹膜透析患者对SARS-CoV-2 mRNA疫苗的长期动态体液反应

Vaccines (Basel). 2022 Oct 18;10(10):1738. doi: 10.3390/vaccines10101738.

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study.血液透析患者在接受SARS-CoV-2 mRNA疫苗加强剂量3个月后的抗刺突抗体：前瞻性SENCOVAC研究

Clin Kidney J. 2022 Jul 26;15(10):1856-1864. doi: 10.1093/ckj/sfac169. eCollection 2022 Oct.

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals.在健康个体中，接种BNT162b2疫苗第三剂后6个月可产生持续高水平的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中和抗体。

Hemasphere. 2022 Jun 21;6(7):e747. doi: 10.1097/HS9.0000000000000747. eCollection 2022 Jul.

Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients.维持性血液透析患者接种BNT162b2新冠疫苗1年后的体液免疫反应动力学

J Nephrol. 2023 Jan;36(1):213-216. doi: 10.1007/s40620-022-01377-y. Epub 2022 Jul 9.

本文引用的文献

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.基于信使核糖核酸的新冠病毒疫苗加强针可诱导针对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和免疫力。

Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6.

Kidney Int. 2021 Dec;100(6):1334-1335. doi: 10.1016/j.kint.2021.10.006. Epub 2021 Oct 14.

Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders.接受维持性血液透析的患者接种新型冠状病毒2疫苗后的体液免疫反应：免疫丧失、第三剂疫苗和无反应者

Nephrol Dial Transplant. 2022 Jan 25;37(2):390-392. doi: 10.1093/ndt/gfab299.

The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays.世卫组织 COVID-19 血清学检测国际标准：推动棘突蛋白检测分析方法的标准化。

Int Immunopharmacol. 2021 Nov;100:108095. doi: 10.1016/j.intimp.2021.108095. Epub 2021 Aug 30.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。

Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.

Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients.血液透析患者完成信使核糖核酸新冠疫苗接种3个月后的抗体维持情况。

Nephrol Dial Transplant. 2021 Dec 2;36(12):2340-2341. doi: 10.1093/ndt/gfab272.

Am J Kidney Dis. 2022 Feb;79(2):185-192.e1. doi: 10.1053/j.ajkd.2021.08.005. Epub 2021 Sep 8.

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.血液透析患者接种3剂BNT162b2 mRNA新冠疫苗后的体液免疫反应。

Kidney Int. 2021 Sep;100(3):702-704. doi: 10.1016/j.kint.2021.06.025. Epub 2021 Jun 30.

Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2.Elecsys Anti-SARS-CoV-2 免疫分析的开发和验证，作为一种高度特异性工具，用于确定过去是否接触过 SARS-CoV-2。

J Clin Microbiol. 2020 Sep 22;58(10). doi: 10.1128/JCM.01694-20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献